Searching for your content...
Phone
877-269-7890 from 8 AM - 10 PM ET
Contact Cision
Phase 2 clinical trial data demonstrate that long-acting buprenorphine (CAM2038), a novel subcutaneous buprenorphine depot formulation, produces an immediate and sustained blockade of opioid effects...
Braeburn Pharmaceuticals ("Braeburn") and Camurus (NASDAQ STO: CAMX) announce four scientific presentations featuring new results from the recently completed clinical development program for...
Braeburn Pharmaceuticals and Camurus (NASDAQ STO: CAMX) announce the presentation of new data from three clinical studies on CAM2038, an investigational long-acting injectable medication with...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.